Re(CO)3([18F]FEDA), a novel 18F PET renal tracer: radiosynthesis and preclinical evaluation
Our previous work demonstrated that the 99mTc renal tracer, 99mTc(CO)3(FEDA) (99mTc-1), has a rapid clearance comparable in rats to that of 131I –OIH, the radioactive gold standard for the measurement of effective renal plasma flow. The uncharged fluoroethyl pendant group of 99mTc-1 provides a route to the synthesis of a structurally analogous rhenium-tricarbonyl 18F renal imaging agent, Re(CO)3([18F]FEDA) (18F-1). Our goal was to develop an efficient one-step method for the preparation of 18F-1 and to compare its pharmacokinetic properties with those of 131I–OIH in rats. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 27, 2017 Category: Nuclear Medicine Authors: Malgorzata Lipowska, Nashwa Jarkas, Ronald J. Voll, Jonathon A. Nye, Jeffrey Klenc, Mark M. Goodman, Andrew T. Taylor Source Type: research
212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models
In this study, we tested the binding of radiolabeled mAb 376.96 to human pancreatic ductal adenocarcinoma (PDAC) cells and localization in xenografts in immune-deficient mice and evaluated 212Pb-labeled 376.96 (212Pb-376 .96) for PDAC therapy. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 23, 2017 Category: Nuclear Medicine Authors: Benjamin B. Kasten, Abhishek Gangrade, Harrison Kim, Jinda Fan, Soldano Ferrone, Cristina R. Ferrone, Kurt R. Zinn, Donald J. Buchsbaum Source Type: research
Evaluation of [18F]FNM biodistribution and dosimetry based on whole-body PET imaging of rats
The aim of this work was to study the biodistribution, metabolism and radiation dosimetry of rats injected with [18F]FNM using PET/CT images. This novel radiotracer targeting NMDA receptor has potential for investigation for neurological and psychiatric diseases. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 21, 2017 Category: Nuclear Medicine Authors: Anne-Sophie Salabert, Erick Mora-Ramirez, Marie Beaurain, Mathieu Alonso, Charlotte Fontan, Hafid Belhadj Tahar, Marie Laure Boizeau, Mathieu Tafani, Manuel Bardi ès, Pierre Payoux Source Type: research
Long-term biodistribution study of HPMA-ran-LMA copolymers in vivo by means of 131I-labeling
For the evaluation of macromolecular drug delivery systems suitable pre-clinical monitoring of potential nanocarrier systems is needed. In this regard, both short-term as well as long-term in vivo tracking is crucial to understand structure-property relationships of polymer carrier systems and their resulting pharmacokinetic profile. Based on former studies revealing favorable in vivo characteristics for 18F-labeled random (ran) copolymers consisting of N-(2-hydroxypropyl)methacrylamide (HPMA) and lauryl methacrylate (LMA) – including prolonged plasma half-life as well as enhanced tumor accumulation – the presented wor...
Source: Nuclear Medicine and Biology - December 15, 2017 Category: Nuclear Medicine Authors: Karolin Wagener, Dorothea Moderegger, Mareli Allmeroth, Achim Reibel, Stefan Kramer, Barbara Biesalski, Nicole Bausbacher, Rudolf Zentel, Oliver Thews, Frank R ösch Source Type: research
Long-term biodistribution study of HPMA-ran-LMA copolymers in vivo by means of 131I –labeling
For the evaluation of macromolecular drug delivery systems suitable pre-clinical monitoring of potential nanocarrier systems is needed. In this regard, both short-term as well as long-term in vivo tracking is crucial to understand structure-property relationships of polymer carrier systems and their resulting pharmacokinetic profile. Based on former studies revealing favorable in vivo characteristics for 18F –labeled random (ran) copolymers consisting of N-(2-hydroxypropyl)methacrylamide (HPMA) and lauryl methacrylate (LMA) – including prolonged plasma half-life as well as enhanced tumor accumulation – the presented ...
Source: Nuclear Medicine and Biology - December 15, 2017 Category: Nuclear Medicine Authors: Karolin Wagener, Dorothea Moderegger, Mareli Allmeroth, Achim Reibel, Stefan Kramer, Barbara Biesalski, Nicole Bausbacher, Rudolf Zentel, Oliver Thews, Frank R ösch Source Type: research
Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 13, 2017 Category: Nuclear Medicine Source Type: research
Table of Contents
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 13, 2017 Category: Nuclear Medicine Source Type: research
Corrigendum to “131I-labeled chitosan hydrogels for radioembolization: a preclinical study in small animals” [Nucl Med Biol 52 (2017) 16–23]
The authors regret that there were typographical errors in the description of 131I Chi biodistribution results. Our 131I Chi biodistribution data were correctly used in Figure 6B. However, the descriptions in the result section ‘Whole body imaging of 131I Chi and biodistribution’ were mistakenly drawn from a wrong data set. This inadvertent error was not detected prior to publication. Below are the correct descriptions. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 7, 2017 Category: Nuclear Medicine Authors: Hyosook Hwang, Kwang Il Kim, JeongIl Kwon, Byoung Soo Kim, Hwan-Seok Jeong, Su Jin Jang, Phil-Sun Oh, Ho Sung Park, Seok Tae Lim, Myung-Hee Sohn, Hwan-Jeong Jeong Tags: Corrigendum Source Type: research
Deuterated 18F-9-O-hexadeutero-3-fluoropropoxyl-(+)-dihydrotetrabenazine (D6-FP-(+)-DTBZ): a vesicular monoamine transporter 2 (VMAT2) imaging agent
Vesicular monoamine transporters 2 (VMAT2) in the brain serve as transporter for packaging monoamine in vesicles for normal CNS neurotransmission. Several VMAT2 imaging agents, [11C]-(+)-DTBZ, dihydrotetrabenazine and [18F]FP-(+)-DTBZ (9-O-fluoropropyl-(+)-dihydro tetrabenazine, a.k.a. [18F]AV-133), are useful for studying the changes in brain function related to monoamine transmission by in vivo imaging. Deuterated analogs have been reported targeting VMAT2 binding sites. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 5, 2017 Category: Nuclear Medicine Authors: Futao Liu, Seok Rye Choi, Zhihao Zha, Karl Ploessl, Lin Zhu, Hank F. Kung Source Type: research
An electrochemical approach for removal of radionuclidic contaminants of Eu from 153Sm for effective use in metastatic bone pain palliation
Thermal neutron activation of 152Sm [152Sm(n, γ)153Sm] using natural or isotopically enriched (by 152Sm) samarium target is the established route for production of 153Sm used for preparation of 153Sm-EDTMP for pain palliation in cancer patients with disseminated bone metastases. However, some long-lived radionuclidic contaminants of Eu, such a s, 154Eu (t½ = 8.6 y) are also produced during the target activation process. This leads to detectable amount of Eu radionuclidic contaminants in patients' skeleton even years after administration with therapeutic doses of 153Sm-EDTMP. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 5, 2017 Category: Nuclear Medicine Authors: Rubel Chakravarty, Sudipta Chakraborty, Mohammed Shahiralam Khan, Ramu Ram, Haladhar Dev Sarma, Ashutosh Dash Source Type: research
68Ga[Ga]-Galmydar: Biodistribution and radiation dosimetry studies in rodents
68Ga[Ga]-Galmydar is an avid transport substrate of ABCB1 (P-Glycoprotein; 170kDa plasma membrane protein), breast cancer resistance protein (BCRP; ABCG2; 72kDa), penetrates human epidermal carcinoma (KB3-1), breast cancer (MCF7), embryonic kidney (HEK 293) tumor cells and rat cardiomyoblasts, and localizes within the mitochondria of tumor and myocardium cells. 68Ga[Ga]-Galmydar excretes from blood pool quickly, and shows stable retention within rat myocardium in vivo for extended periods, therefore, the agent shows potential to enable myocardial perfusion imaging. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 1, 2017 Category: Nuclear Medicine Authors: Jothilingam Sivapackiam, Richard Laforest, Vijay Sharma Source Type: research
68Ga-Galmydar: Biodistribution and Radiation Dosimetry Studies in Rodents
68Ga-Galmydar is an avid transport substrate of ABCB1 (P-Glycoprotein; 170kDa plasma membrane protein), breast cancer resistance protein (BCRP; ABCG2; 72kDa), penetrates human epidermal carcinoma (KB3 –1), breast cancer (MCF7), embryonic kidney (HEK 293) tumor cells and rat cardiomyoblasts, and localizes within the mitochondria of tumor and myocardium cells. 68Ga-Galmydar excretes from blood pool quickly, and shows stable retention within rat myocardium in vivo for extended periods, therefore, the agent shows potential to enable myocardial perfusion imaging. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 1, 2017 Category: Nuclear Medicine Authors: Jothilingam Sivapackiam, Richard Laforest, Vijay Sharma Source Type: research
Editorial Board
(Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 27, 2017 Category: Nuclear Medicine Source Type: research
